Применение комбинации β2-агониста и М-холинолитика для лечения бронхиальной астмы
Применение комбинации β2-агониста и М-холинолитика для лечения бронхиальной астмы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Riccioni G, D'Orazio N, Di Ilio C et al. Quality of Life and clinical symptoms in asthmatic subjects. J Asthma 2004; 41: 85–9.
2. Глобальная стратегия лечения и профилактики бронхиальной астмы. Под ред. А.Г.Чучалина. М.: Изд-кий дом «Атмосфера», 2007.
3. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention. 2006. http://www.ginasthma.com
4. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–78.
5. Емельянов А.В., Федосеев Г.Б., Сергеева Г.Р.и др. Распространенность бронхиальной астмы и аллергического ринита среди взрослого населения Санкт-Петербурга. Аллергология. 2002; 2: 10–5.
6. Wertz DA, Pollack M, Rodgers K. Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann Allergy Asthma Immunol 2010; 105 (2): 118–23.
7. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009; 4: CD005307.
8. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010; 4: CD005533.
9. Global Strategy for Asthma Management and Prevention. Revised 2009 The GINA reports are available on www.ginasthma.org
10. Gelb AF, Karpel J, Wise RA et al. Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008; 21 (4): 630–6.
11. Donohue J. Combination therapy for COPD. Proc Am Thorac Soc 2005; 2: 72–81.
12. Ahmad Z, Singh SK. Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics. J Asthma 2010; 47 (3): 340–3.
13. Boaventura LC, Araujo AC, Martinez JB, Vianna EO. Effects of ipratropium on exercise-induced bronchospasm. Int J Sports Med 2010; 31 (7): 516–20.
14. Oraka E, King ME, Callahan DB. Asthma and serious psychological distress: prevalence and risk factors among US adults, 2001-2007. Chest 2010; 37 (3): 609–16.
15. Ritz T, Kullowatz A, Goldman MD. Airway response to emotional stimuli in asthma: the role of the cholinergic pathway. J Appl Physiol 2010; 108 (6): 1542–9.
16. Schlueter D.P. Ipratropium bromide in asthma: A review of the literature The Am J Med 1986; 81 (5, Suppl. 1), 55–60.
17. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. Respir Res 2007; 6; 8: 19.
2. Глобальная стратегия лечения и профилактики бронхиальной астмы. Под ред. А.Г.Чучалина. М.: Изд-кий дом «Атмосфера», 2007.
3. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention. 2006. http://www.ginasthma.com
4. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–78.
5. Емельянов А.В., Федосеев Г.Б., Сергеева Г.Р.и др. Распространенность бронхиальной астмы и аллергического ринита среди взрослого населения Санкт-Петербурга. Аллергология. 2002; 2: 10–5.
6. Wertz DA, Pollack M, Rodgers K. Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann Allergy Asthma Immunol 2010; 105 (2): 118–23.
7. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009; 4: CD005307.
8. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010; 4: CD005533.
9. Global Strategy for Asthma Management and Prevention. Revised 2009 The GINA reports are available on www.ginasthma.org
10. Gelb AF, Karpel J, Wise RA et al. Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008; 21 (4): 630–6.
11. Donohue J. Combination therapy for COPD. Proc Am Thorac Soc 2005; 2: 72–81.
12. Ahmad Z, Singh SK. Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics. J Asthma 2010; 47 (3): 340–3.
13. Boaventura LC, Araujo AC, Martinez JB, Vianna EO. Effects of ipratropium on exercise-induced bronchospasm. Int J Sports Med 2010; 31 (7): 516–20.
14. Oraka E, King ME, Callahan DB. Asthma and serious psychological distress: prevalence and risk factors among US adults, 2001-2007. Chest 2010; 37 (3): 609–16.
15. Ritz T, Kullowatz A, Goldman MD. Airway response to emotional stimuli in asthma: the role of the cholinergic pathway. J Appl Physiol 2010; 108 (6): 1542–9.
16. Schlueter D.P. Ipratropium bromide in asthma: A review of the literature The Am J Med 1986; 81 (5, Suppl. 1), 55–60.
17. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. Respir Res 2007; 6; 8: 19.
Авторы
К.А.Зыков
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.